A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes

Journal of Virological Methods
Kristel Van LaethemAnne-Mieke Vandamme

Abstract

Recently, the Food and Drug Administration (FDA) of the USA approved the first integrase inhibitor for inclusion in treatment regimens of HIV-1 patients failing their current regimens with multi-drug resistant strains. However, treatment failure has been observed during integrase inhibitor-containing therapy. Several mutational pathways have been described with signature mutations at integrase positions 66, 92, 148 and 155. Therefore, a genotypic assay for the amplification and sequencing of HIV-1 integrase was developed. The assay displayed a detection limit of 10 HIV-1 III(B) RNA copies/ml plasma. As the HIV-1 pandemic is characterised by a large genetic diversity, the new assay was evaluated on a panel of 74 genetically divergent samples belonging to the following genetic forms A, B, C, D, F, G, J, CRF01-AE, CRF02-AG, CRFF03-AB, CRF12-BF and CRF13-cpx. Their viral load ranged from 178 until >500,000 RNA copies/ml. The amplification and sequencing was successful for 70 samples (a success rate of 95%). The four failures were most probably due to low viral load or poor quality of RNA and not to subtype issues. Some of the sequences obtained from integrase inhibitor-naïve patients displayed polymorphisms at integrase positions a...Continue Reading

References

Sep 28, 2001·The Journal of Infectious Diseases·C F PernoUNKNOWN Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group
Apr 13, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Joke SnoeckAnne-Mieke Vandamme
Aug 4, 2005·Bioinformatics·Tulio de OliveiraAnne-Mieke Vandamme
Oct 6, 2006·Bioinformatics·K DeforcheUNKNOWN non-B Workgroup
Nov 28, 2006·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·K DeforcheA-M Vandamme
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Isabelle MaletAnne-Geneviève Marcelin
Mar 11, 2008·AIDS Research and Human Retroviruses·Jurgen VercauterenKristel van Laethem

❮ Previous
Next ❯

Citations

Apr 10, 2010·AIDS Research and Human Retroviruses·Muhammad Q FishMaria A Papathanasopoulos
Sep 15, 2010·AIDS Research and Human Retroviruses·Panasda Isarangkura-Na-AyuthayaMasanori Kameoka
Dec 25, 2012·BMC Infectious Diseases·Miłosz ParczewskiAnna Boroń-Kaczmarska
Apr 10, 2012·PloS One·Atila IamarinoPaolo Marinho de Andrade Zanotto
Dec 24, 2013·International Journal of Antimicrobial Agents·Jaqueline de Souza CavalcantiUNKNOWN São Paulo Salvage Workgroup
Mar 2, 2011·Journal of Medical Virology·Bluma G BrennerMichel Roger
Jul 28, 2013·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Sabrina Wai-Chi ToWing-Cheong Yam
May 9, 2012·Antiviral Research·Jaqueline Souza CavalcantiLuís Fernando de Macedo Brígido
Oct 16, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J-Y KimS S Kim
Jan 1, 2019·The Journal of Antimicrobial Chemotherapy·Santiago Ávila-RíosUNKNOWN HIVDR MexNet Group
Dec 21, 2019·Journal of the International AIDS Society·Amalia Girón-CallejasGustavo Reyes-Terán
Jun 19, 2021·Scientific Reports·Miłosz ParczewskiPiotr Grabarczyk
Aug 18, 2021·Scientific Reports·Karol SerwinMiłosz Parczewski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Tommy F Liu, Robert W Shafer
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Luke C SwensonP Richard Harrigan
The Lancet Infectious Diseases
L P R VandekerckhoveEuropean Consensus Group on clinical management of tropism testing
© 2022 Meta ULC. All rights reserved